About: CD4 T(RM) Cells Following Infection and Immunization: Implications for More Effective Vaccine Design

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: CD4 T(RM) Cells Following Infection and Immunization: Implications for More Effective Vaccine Design Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	CD4 T(RM) Cells Following Infection and Immunization: Implications for More Effective Vaccine Design
Creator	Mills, Kingston Wilk, Mieszko Mckinstry, Karl Tartour, Eric
Source	Medline; PMC
abstract	The induction of immunological memory, which is mediated by memory T and B cells, is central to adaptive protective immunity to pathogens induced by previous infection and is the cornerstone of effective vaccine design. Recent studies in mice have suggested that memory T cells that accumulate in tissues, termed tissue-resident memory T (T(RM)) cells, play a crucial role in maintaining long-term protective immunity to mucosal pathogens. CD4 and CD8 T(RM) cells can be induced following infection at mucosal sites or the skin, where they are maintained and poised to respond rapidly to reinfection with the same pathogen. T(RM) cells can also be generated by vaccination, but their induction is influenced by a number of factors, including the type of vaccine, the adjuvant, and the route of immunization. Live attenuated vaccines appear to be more effective than killed or subunit vaccines at inducing T(RM) cells and mucosal immunization, especially by intranasal route, is more effective than parenteral delivery. However, evidence is emerging that formulation of killed or subunit vaccines with novel adjuvants, especially those that generate Th1 and Th17 responses, can promote the induction of T(RM) cells. While T(RM) cells are also present at high number in mucosal tissues in humans, one of the challenge will be to develop methodologies for routine quantification of these cells in humans. Nevertheless, the identification of approaches for optimum induction of T(RM) cells in mice should assist in the design of more effective vaccines that sustain protective immunity against a range of human pathogens.
has issue date	2018-08-10(xsd:dateTime)
bibo:doi	10.3389/fimmu.2018.01860
bibo:pmid	30147701
has license	cc-by
sha1sum (hex)	30215fe783662edff46565307706587b3bdd60a5
schema:url	https://doi.org/10.3389/fimmu.2018.01860
resource representing a document's title	CD4 T(RM) Cells Following Infection and Immunization: Implications for More Effective Vaccine Design
has PubMed Central identifier	PMC6095996
has PubMed identifier	30147701
schema:publication	Front Immunol
resource representing a document's body	covid:30215fe783662edff46565307706587b3bdd60a5#body_text
is schema:about of	named entity 'VACCINE DESIGN' named entity 'EFFECTIVE' named entity 'TRM' named entity 'TRM' named entity 'pathogens' named entity 'CD8' named entity 'Immunology' named entity 'implications' named entity 'QUANTIFICATION' named entity 'B CELLS' named entity 'EFFECTIVE' named entity 'MAINTAINING' named entity 'HUMANS' named entity 'NOVEL' named entity 'DELIVERY' named entity 'IMMUNOLOGICAL MEMORY' named entity 'PARENTERAL' named entity 'FOLLOWING' named entity 'TRM' named entity 'INTRANASAL ROUTE' named entity 'HUMAN' named entity 'ADJUVANT' named entity 'GENERATED' named entity 'POISED' named entity 'CD8' named entity 'BUT' named entity 'TH1' named entity 'WHERE' named entity 'PATHOGENS' named entity 'INFECTION' named entity 'IMMUNIZATION' named entity 'FORMULATION' named entity 'THEIR' named entity 'RAPIDLY' named entity 'INDUCING' named entity 'LIVE' named entity 'ONE OF' named entity 'ASSIST' named entity 'HIGH' named entity 'VACCINE' named entity 'INDUCTION' named entity 'PLAY' named entity 'CELLS' named entity 'MEMORY T CELLS' named entity 'TH17' named entity 'IMMUNIZATION' named entity 'TISSUES' named entity 'MICE' named entity 'PRESENT' named entity 'VACCINE DESIGN' named entity 'FOLLOWING' named entity 'JOURNAL ' named entity 'SECTION' named entity 'STUDIES' named entity 'MEDIATED' named entity 'CD4' named entity 'PREVIOUS' named entity 'ADAPTIVE' named entity 'VACCINES' named entity 'ROUTINE' named entity 'PROTECTIVE IMMUNITY' named entity 'IDENTIFICATION' named entity 'RECENT' named entity 'TO RESPOND' named entity 'IMMUNOLOGY' named entity 'CD4' named entity 'INFECTION' named entity 'PATHOGEN' named entity 'CELLS' named entity 'NUMBER OF FACTORS' named entity 'RESIDENT' named entity 'SKIN' named entity 'TYPE' named entity 'REINFECTION' named entity 'EVIDENCE' named entity 'ATTENUATED VACCINES' named entity 'INDUCED' named entity 'SITES'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software